To ask the Scottish Executive whether it has carried out an evaluation of the implementation of the guidance, Introduction and Availability of Newly Licensed Medicines in the NHS in Scotland (CEL17), from the perspective of (a) NHS boards, (b) healthcare professionals and (c) patients and, if so, what the outcome was.